LEADING ARTICLES


Empiricities—travellers' health MYRON G SCHULTZ .......................... 582

Preterm rupture of the membranes JAMES OWEN DRIFE . 583

Ketoconazole RODERICK HAY ........................................... 584

Regular Review: Postmenopausal osteoporosis J C STEVENSON, M I WHITEHEAD . 585

CLINICAL RESEARCH • PAPERS AND SHORT REPORTS • PRACTICE OBSERVED

Dietary protein energy supplementation of pregnant Asian mothers at Sorrento, Birmingham

I: Unselective during second and third trimesters O A C VIEGAS, P H SCOTT, T J COLE, H N MANSFIELD, PAMELA WHARTON, B A WHARTON 589

II: Selective during third trimester only O A C VIEGAS, P H SCOTT, T J COLE, PHYLLIS EATON, P G NEEDHAM, B A WHARTON .......................... 592

Influence of previous gold toxicity on subsequent development of penicillamine toxicity

P J SMITH, W R SWINBURN, D R SWINSON, I M STEWART .......................... 595

Fractures on the chest radiograph in detection of alcoholic liver disease DAVID R M LINDSELL, ALAN G WILSON, J DOUGLAS MAXWELL . 597

 Relationship between cigarette yields, puffing patterns, and smoke intake: evidence for tar compensation?

S R SUTTON, M A H RUSSELL, R IYER, C FAYERABEND, Y SALOJEE .......................... 600

Mesothelomas and asbestos type in asbestos textile workers: a study of lung contents J C WAGNER, G BERRY, F D POOLEY .......................... 603

Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology?

D J DAVIES, J E MORAN, J F NIALL, G B RYAN .......................... 606

Molluscum contagiosum: an unusual complication of tattooing IS POULDS .......................... 607

Hypocalcaemia-induced epilepsy during lactation R A HARRAD, P G E KENNErY .......................... 607

Double-blind controlled study of primidone in essential tremor: preliminary results L J FINDLEY, S CALZETTI .......................... 608

Research in General Practice: Sterilisation of women: prevalence and outcome ALASTAIR F WRIGHT .......................... 609

Practising Prevention: Adults C T DONOVAN .......................... 612

Making a visit: an American GP practising in the NHS JOHN J FREY .......................... 614

MEDICAL PRACTICE

Attendance at a breast screening clinic: a problem of administration or attitudes

K FRENCH, A M D PORTER, S E ROBINSON, F M MCCALLUM, J G R HOWIE, M M ROBERTS .......................... 617

Scandinavian and Dutch lessons in childhood road traffic accident prevention J G AVERY, P J AVERY .......................... 621

ABC of Diabetes: Nephropathy PETER J WATKINS .......................... 627

Diagnosis and treatment of venous thromboembolism by consultants in Scotland A G PRENTICE, G D O LOWE, C D FORBES .......................... 630

Causes of death in sickle-cell disease in Jamaica ANTHONY N THOMAS, CATHERINE PATTISON, GRAHAM R SERJEANT .......................... 633

Letter from Chicago: A little showmanship GEORGE DUNEA .......................... 636

Any Questions? ........................................... 620, 626, 632

Materia Non Medica—Contribution from PRADIP K DATTA .......................... 635

Medicine and Books ........................................... 638

What's new in the new editions? CLIFFORD HAWKINS .......................... 642

Personal View ANDREW R POTTER .......................... 644

CORRESPONDENCE—List of Contents .......................... 645

OBITUARY .......................... 660

NEWS AND NOTES

Views ........................................... 656

Medicolegal—Contempt of Court ........................................... 657

Medical News—Double issue of BMJ ........................................... 659

BMA Notices ........................................... 659

SUPPLEMENT

NHS reorganisation: Getting down to units ALAN BUSSEY . 663

Vocational training: three-year mandatory course ........................................... 664

Annual reviews or no annual reviews: the balance of power between the DHSS and health authorities DAVID E ALLEN 665

Surgeons introduce scheme to help sick doctors ........................................... 667

Confidentiality and the police: guidelines in Scotland ........................................... 668

Buying added years ........................................... 668

New CEC chairman ........................................... 668

NO 6342 BRITISH MEDICAL JOURNAL 1982 VOLUME 285 581-668

BRITISH MEDICAL ASSOCIATION TAVISTOCK SQUARE LONDON WC1H 9JR.

WEEKLY. ISSN 0007-1447

CORRESPONDENCE

Side effects of benoxaprofen
M F Shadforth, MRCP, and others

Benoxaprofen
A L Macnair, MB; G R Horton, MB; C D E Morris, MRCP; J Hawthor, MRCP; T C Hindson, FRCP; N G M Legg, FRCPED; V Cooper, MRCP; C W K Willard, MB

Ethics and in-vitro fertilisation
M Potter, MB

Brodrick exhumed again
H H Pilling, MB

Avoidance of tracheostomy in sleep apnoea syndrome
N H Jenkins, MB; Kate A H Wheeler, MRCP; C A A H Water, FRCPED; P J Thompson, FRCP, and Elizabetha Sawicka, MRCP

First seven years of a new NHS mental handicap service 1974-81
T L Pilkington, FRCPych

Birth asphyxia
Janet A Eyre, MB, and others

Genito-urinary medicine
M D Talbot, MRCP

Sphygmomanometers in hospital and family practice
T J Thornton, MB; T C O'Dowd, MRCP; Anna E Livingstone, MB

Water intoxication and oxytocin
B H Valentine, FRCS

Atropine poisoning in early infancy due to Eumydrin drops
Cynthia M Illingworth, FRCP, and others

Do alcoholics recover?
D H Maiton, FRCPych

Strengths and weaknesses of British medicine
R Law, FRCP

Malalignment of the shoulder after stroke
G J Carpenter, MRCP

Reversible hypothryroidism in adrenal insufficiency
W J Jeffcoate, MRCP, and J R E Davis, MRCP

Guillain-Barré syndrome associated with first presentation of antiphospholipid antibodies
T D Watts, FRCP; G K Molnar, MD, and others

Impact of maternal serum alpha-fetoprotein screening on antenatal diagnosis
Susan J Standing, BSC, and others

Left-handedness
P O Behan, FRCP

Inaccuracy of London School of Hygiene spaghmomanometer
G Nyberg, MD, and others

Electrocardiographic abnormalities and autonomic dysfunction in Guillain-Barré syndrome
A Hagen, MB, FRCPATH; I K Malmberg, MD

Fees for cervical smears
P N Bamford, MRCPG, and others

Coronary disease
H S Wright, FRCS, and A R Bailey, MRCP

Managing cerebral malaria
L J Bruce-Chwatt, FRCP

Nifuroxantan-induced parotiditis
J P Griffin, MRCP, and R G Penn, MB

Laboratory dispute in Fife
L G Whitty, FRCPATH

Whom does BUPA care for?
S L Kaye, MD; D L Gullick, MB

Pathology and university cuts
K McCarthy, FRCPATH, and J D Williams, MD

Authors of the world unite

Points
The arms race and health care (S E Ramsbotham); Side effects of benoxaprofen (Milena Lesza); Health Service strikes (Rita Henryk-Gutt; S K Ghosh); Medical cover for Sikh women (P G Nield); Banning boxing (A Rickards); Women in medicine (Margaret G Anderson; Mary Ducrow); Ethical conflicts (J Finlayson); You may die from 'old age,' but if you do you may not be cremated (M K Williams)

We may return unduly long letters to the author for shortening so that we can offer readers as wide a selection as possible.

We receive so many letters each week that we have to omit some of them. Letters should be typed with double spacing between lines and must be signed personally by all their authors, who should include their degrees. We cannot acknowledge their receipt unless a stamped addressed envelope or an international reply coupon is enclosed.

Correspondents should present their references in the Vancouver style (see examples in these columns). In particular, the names and initials of all authors must be given unless there are more than six, when only the first three should be given, followed by et al: and the first and last page numbers of articles and chapters should be included. Titles of papers are not, however, included in the correspondence section.

Side effects of benoxaprofen

Sr,—On 10 July (p 136) you published, alongside a letter from one of us (Dr M F Shadforth) pointing out the probable long-term benefits from benoxaprofen in rheumatoid arthritis, several other letters cautioning that the side effects of this drug were being overstated. These letters suggested that time was required to assess the drug and that a hasty decision from the Committee on Safety of Medicines would be ill advised. Perhaps the Committee on Safety of Medicines was subject to other pressures, but it did not heed the advice, since on 4 August it suspended benoxaprofen. It did not give the profession opportunity to comment, stating that urgent action was required. Why then did it not suspend the drug on 25 July? Perhaps all 3500 adverse effects and 61 deaths occurred that week. The side effects of benoxaprofen in this centre were insignificant when compared with the benefits it provided. We have many patients who developed photosensitivity but requested that they continue the drug since the unwanted effect was preferable to the arthritis. We have patients now imporing us to obtain continuous supplies to keep their disease controlled. It seems we cannot do this and they will need to revert to other agents requiring full hospital surveillance. Almost certainly some of them will suffer uncomfortable, or even life-threatening, side effects which could have been avoided had they remained on benoxaprofen. By first announcing its decision to the popular press the Committee on Safety of Medicines ensured that patients would approach us when we had insufficient information to make considered decisions. It has effectively abolished the drug worldwide. This agent was synthesised and developed in Britain. Which country would allow it to be marketed when the parent country announces it is too hazardous to distribute? Distal Products, or their parent, Eli Lilly Industries, had no option but to withdraw the drug throughout. Rheumatology has lost a potentially valuable agent.

Mistakes occur and can be forgiven. Repeated mistakes require correction. It appears that this is not the first time the Committee on Safety of Medicines has taken such a course, approaching the popular press before the profession, since we have learnt of many decisions of the Committee on Safety of Medicines from the papers before our official communication. One of us has still not received an official communication on the present matter. Nor is this the first agent with disease-modifying properties in rheumatoid arthritis to be withdrawn because of the surveillance of the Committee on Safety of Medicines. Imperial Chemical Industries abandoned Cloxic just before the drug was marketed. This was almost certainly because it felt the Committee on Safety of Medicines would not accept the incidence of side effects. This drug, too, promised to have disease-modifying